Drug Discovery World

SEPTEMBER 6, 2024

Vincent Carrère, CEO of NH TherAguix, added: “This first positive step paves the way for the major next inflexion point expected in the second half of the year regarding the interim efficacy analysis of AGuIX.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

Drug Discovery World

APRIL 18, 2023

billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.

Therapies 242

Therapies Clinical Development Treatment Marketing 242

Drug Discovery World

MAY 23, 2024

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. This study is anticipated to read out in 2H of 2026.

Clinical Trials 130

Clinical Trials Trials Clinical Development Treatment 130

Drug Discovery World

NOVEMBER 23, 2023

“The initiation of enrollment will enable Minoryx to take the final steps towards US approval of leriglitazone for treatment of X-ALD patients.” “Minoryx has begun an extensive pre-screening program aimed at identifying additional eligible patients.

Trials 130

Trials Clinical Trials FDA Approval FDA 130

The Pharma Data

OCTOBER 31, 2020

Food and Drug Administration (“FDA”) has approved the Investigation New Drug (IND) application for TG-1000, a novel treatment for influenza A and B. With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. billion USD by 2026 at a CAGR of 11.5%. TAIPEI, Taiwan , Nov.

FDA Approval 52

FDA Approval FDA Virus Clinical Development 52

Drug Discovery World

OCTOBER 4, 2022

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. million as part of a collaborative project aimed at finding new treatments for motor neurone disease (MND).

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

APRIL 6, 2022

“With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.” ” Integrating Pharmaceuticals and Oncology business units.

International 52

International Pharmaceuticals Drug Development Compliance 52